About Geneuro sa
Geneuro SA: Pioneering the Development of Therapeutics for Nervous System Pathologies Involving Human Endogenous Retroviruses (HERVs)
Geneuro SA is a Swiss-based biopharmaceutical company that specializes in developing innovative therapeutics to address nervous system pathologies involving human endogenous retroviruses (HERVs). The company was founded in 2006 by Dr. François Curtin and Dr. Hervé Perron, two renowned scientists with extensive experience in the field of neurology and virology.
The HERV hypothesis proposes that certain neurological diseases, such as multiple sclerosis (MS), are caused by the activation of HERVs, which are remnants of ancient retroviral infections that have become part of our genome. Geneuro's mission is to develop safe and effective treatments that target these HERV-related mechanisms, with the ultimate goal of improving patients' quality of life.
Geneuro's lead product candidate is temelimab (formerly known as GNbAC1), a monoclonal antibody that targets a specific protein derived from a HERV called MSRV-Env. Temelimab has shown promising results in clinical trials for MS, demonstrating significant reductions in disease activity and disability progression compared to placebo.
In addition to MS, Geneuro is also exploring the potential applications of temelimab in other neurological disorders such as amyotrophic lateral sclerosis (ALS) and type 1 diabetes. The company has also developed a second-generation antibody called GNbAC2, which targets another HERV-derived protein called pHERV-W Env.
Geneuro's innovative approach has attracted significant interest from investors and partners alike. In 2018, the company raised CHF 22 million ($22 million) through an oversubscribed private placement to fund its ongoing clinical development programs. Geneuro has also established collaborations with leading academic institutions such as Harvard Medical School and INSERM (the French National Institute of Health and Medical Research).
Geneuro's team of experts includes scientists, clinicians, and business professionals with a shared passion for advancing the field of neurology. The company's headquarters are located in Plan-les-Ouates, near Geneva, Switzerland.
In conclusion, Geneuro SA is a pioneering biopharmaceutical company that is leading the way in developing innovative therapeutics for nervous system pathologies involving HERVs. With its cutting-edge research and development programs, strong partnerships, and dedicated team of experts, Geneuro is poised to make a significant impact on the lives of patients suffering from these debilitating diseases.